DR. JOHN C HISERODT, M.D.
Medical Practice in Irvine, CA

6277368, Aug 21, 2001

Jul 24, 1997

8/901225

John C. Hiserodt - Huntington Beach CA
Martin R. Graf - Richmond VA
Gale A. Granger - Laguna Beach CA

The Regents of the University of California - Oakland CA

A01N 6300, C12N 1585, A61K 3512, A61K 3519

424 9321

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-. alpha. , and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

7175839, Feb 13, 2007

Sep 29, 1998

09/162648

John C. Hiserodt - Huntington Beach CA, US

Meyer Pharmaceuticals LLC - Irvine CA

A01N 63/00, C12N 5/00, C12N 5/02, C12P 19/28

424 931, 424 933, 435 851, 435 857, 435325, 435373, 435375, 435810

This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.

7264820, Sep 4, 2007

Jun 5, 2001

09/875823

John C. Hiserodt - Huntington Beach CA, US
Martin R. Graf - Richmond VA, US
Gale A. Granger - Laguna Beach CA, US

The Regents of the University of California - Oakland CA

A61K 39/00

4242771

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

7364726, Apr 29, 2008

Jun 5, 2001

09/875349

John C. Hiserodt - Huntington Beach CA, US
Martin R. Graf - Richmond VA, US
Gale A. Granger - Laguna Beach CA, US

The Regents of the University of California - Oakland CA

A61K 48/00

424 932

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

2008005, Mar 6, 2008

Aug 31, 2007

11/897993

John Hiserodt - Huntington Beach CA, US
Martin Graf - Richmond VA, US
Gale Granger - Laguna Beach CA, US

A61K 38/19, A61K 38/20, A61K 39/385

424085200, 424193100, 514012000

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

2008007, Mar 27, 2008

Jun 29, 2007

11/824480

John Hiserodt - Huntington Beach CA, US
Martin Graf - Richmond VA, US
Gale Granger - Laguna Beach CA, US

A61K 35/00, A61K 39/00, A61P 43/00, C12N 15/87

424277100, 424093210, 435455000

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

6207147, Mar 27, 2001

Oct 10, 1997

8/948939

John C. Hiserodt - Huntington Beach CA
James A. Thompson - Aliso Viejo CA
Gale A. Granger - Laguna Beach CA

The Regents of the University of California - Oakland CA

A01N63/00, 7, C12N5/06, 5/08, 5/02

424 931

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise stimulated lymphocytes allogeneic to the subject being treated, along with a source of tumor-associated antigen. The allogeneic lymphocytes can be stimulated by combining or coculturing them with leukocytes obtained from the subject to be treated or from another third-party donor. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. Stimulated allogeneic lymphocytes and tumor antigen are combined and administered at a site distant from the primary tumor, in order to prime or boost a systemic cellular anti-tumor immune response. This approach overcomes the natural refractory nature of the immune system to stimulation by tumor antigens, generating a host response and potentially improving the clinical outcome.

7361332, Apr 22, 2008

Jan 26, 2001

09/771263

Gale Arthur Granger - Laguna Beach CA, US
John C. Hiserodt - Huntington Beach CA, US
James Thompson - Ladera Ranch CA, US

The Regents of the University of California - Oakland CA

A01N 63/00

424 931

This invention provides methods and compositions for treating tumors. The cell population is made up of alloactivated lymphocytes from the patient or from one or more third-party donors that are alloactivated in a mixed lymphocyte culture. It can be placed into the tumor bed, or combined with tumor-associated antigen for administration to a distal site as a vaccine. The compositions recruit activated participation of the host Immune system, which then reacts against the tumor and provides a level of ongoing protection. Employing multiple third party donor cells confers particular advantages in terms of effectiveness, timing, and ease of use.

2008022, Sep 11, 2008

Sep 12, 2007

11/854014

James Thompson - Ladera Ranch CA, US
Gale Arthur Granger - Laguna Beach CA, US
John C. Hiserodt - Huntington Beach CA, US

A61K 39/00, A61K 35/12, A61P 35/00

4242771, 424 937

This invention provides methods and compositions for treating tumors. The cell population is made up of alloactivated lymphocytes from the patient or from one or more third-party donors that are alloactivated in a mixed lymphocyte culture. It can be placed into the tumor bed, or combined with tumor-associated antigen for administration to a distal site as a vaccine. The compositions recruit activated participation of the host Immune system, which then reacts against the tumor and provides a level of ongoing protection. Employing multiple third party donor cells confers particular advantages in terms of effectiveness, timing, and ease of use.